Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Sigilon Therapeutics stock | $5.55

Learn how to easily invest in Sigilon Therapeutics stock.

Sigilon Therapeutics Inc
- $0.02 ( - 0.36%)

Sigilon Therapeutics Inc is a biotechnology business based in the US. Sigilon Therapeutics shares (SGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Sigilon Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Sigilon Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SGTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Sigilon Therapeutics stock price (NASDAQ: SGTX)

Use our graph to track the performance of SGTX stocks over time.

Sigilon Therapeutics shares at a glance

Information last updated 2021-10-16.
Latest market close$5.55
52-week range$4.33 - $54.32
50-day moving average $5.69
200-day moving average $9.44
Wall St. target price$20.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.32

Buy Sigilon Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sigilon Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sigilon Therapeutics price performance over time

Historical closes compared with the close of $5.55 from 2021-10-15

1 week (2021-10-11) 4.91%
1 month (2021-09-17) -9.17%
3 months (2021-07-16) -6.25%
6 months (2021-04-16) -67.43%
1 year (2020-10-14) N/A
2 years (2019-10-14) N/A
3 years (2018-10-14) N/A
5 years (2016-10-14) N/A

Sigilon Therapeutics financials

Revenue TTM $13.6 million
Gross profit TTM $-40,114,000
Return on assets TTM -29.89%
Return on equity TTM -107.52%
Profit margin 0%
Book value $3.49
Market capitalisation $177.9 million

TTM: trailing 12 months

Shorting Sigilon Therapeutics shares

There are currently 777,389 Sigilon Therapeutics shares held short by investors – that's known as Sigilon Therapeutics's "short interest". This figure is 1% up from 769,355 last month.

There are a few different ways that this level of interest in shorting Sigilon Therapeutics shares can be evaluated.

Sigilon Therapeutics's "short interest ratio" (SIR)

Sigilon Therapeutics's "short interest ratio" (SIR) is the quantity of Sigilon Therapeutics shares currently shorted divided by the average quantity of Sigilon Therapeutics shares traded daily (recently around 217147.76536313). Sigilon Therapeutics's SIR currently stands at 3.58. In other words for every 100,000 Sigilon Therapeutics shares traded daily on the market, roughly 3580 shares are currently held short.

To gain some more context, you can compare Sigilon Therapeutics's short interest ratio against those of similar companies.

However Sigilon Therapeutics's short interest can also be evaluated against the total number of Sigilon Therapeutics shares, or, against the total number of tradable Sigilon Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sigilon Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Sigilon Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.053% of the tradable shares (for every 100,000 tradable Sigilon Therapeutics shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sigilon Therapeutics.

Find out more about how you can short Sigilon Therapeutics stock.

Sigilon Therapeutics share dividends

We're not expecting Sigilon Therapeutics to pay a dividend over the next 12 months.

Sigilon Therapeutics overview

Sigilon Therapeutics, Inc. , a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017.

Frequently asked questions

What percentage of Sigilon Therapeutics is owned by insiders or institutions?
Currently 21.908% of Sigilon Therapeutics shares are held by insiders and 61.183% by institutions.
How many people work for Sigilon Therapeutics?
Latest data suggests 99 work at Sigilon Therapeutics.
When does the fiscal year end for Sigilon Therapeutics?
Sigilon Therapeutics's fiscal year ends in December.
Where is Sigilon Therapeutics based?
Sigilon Therapeutics's address is: 100 Binney Street, Cambridge, MA, United States, 02142
What is Sigilon Therapeutics's ISIN number?
Sigilon Therapeutics's international securities identification number is: US82657L1070

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site